Having trouble accessing articles? Reset your cache.

Complete response to NK cell therapy prompts NantKwest to plan pivotal trials

NantKwest is planning registration trials for its off-the-shelf NK cell therapy in triple-negative breast cancer and pancreatic cancer after compassionate use of PD-L1.t-haNK led to a complete response in one patient.

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers